Sygnature Discovery completes major acquisition of NuChem Sciences, one of North America’s largest drug discovery contract research organizations.
This third acquisition in the last 16 months is part of Sygnature Discovery’s growth plan. This acquisition will enable Sygnature Discovery to expand its global footprint and business operations and, more specifically, its service offering in North America. Sygnature Discovery will also be positioned to leverage new drug discovery expertise in the North American market. Following this acquisition, Sygnature Discovery will have more than 1,000 employees across 53 nationalities, including 900 scientists working on drug discovery programs, a commitment to diversity that reflects NuChem Sciences’ corporate values.
NuChem Sciences was supported by several collaborators including Amorchem, Investissement Québec, Fonds de Solidarité FTQ and the Business Development Bank of Canada.
After guiding NuChem Sciences through two acquisitions and several rounds of debt and equity financing in the last two years, Fasken advised NuChem Sciences and its shareholders on this large-scale sale transaction with a team that included Vincent Girard, Anne-Marie Naud, Michaëlle Guilbault, Anne-Sophie Godbout and Ali Aziez. This transaction proved to be complex due to its cross-border nature and the need to strike a balance between the interests of many shareholders, including a number of institutional ones.
Jurisdiction
- Québec
